Novartis announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, which overshadowed a modest outlook raise. Novartis CEO Vasant Narasimham speaks with Bloomberg's Scarlet Fu on the impact of pharma tariffs.

<p>Novartis announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, which overshadowed a modest outlook raise. Novartis CEO Vasant Narasimham speaks with Bloomberg's Scarlet Fu on the impact of pharma tariffs.</p>

Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment.

<p>Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment.</p>

Listen to top interviews from Bloomberg News.

Bloomberg Talks

Novartis CEO Vas Narasimhan Talks Psoriasis Drug, China Growth, M&A

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/30c9cbcb-02f8-438f-90e7-b31d014d51ef/transcript

Advertisement